Corporal Michael J. Cresencz Veterans Affairs Medical Center and the Perelman School of Medicine at the University of Pennsylvania, University Avenue, Philadelphia, PA 19104, USA.
University of Notre Dame Australia/Marian Centre, 200 Cambridge Street, Perth 6014, Australia.
J Neurol Sci. 2018 Jun 15;389:4-9. doi: 10.1016/j.jns.2018.02.015. Epub 2018 Feb 3.
Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications. Although uncertainty and concern about this drug side effect have vacillated since its initial recognition 60 years ago, recent commercial interest in developing effective treatments has rekindled scientific and clinical interest after a protracted period of neglect. Although substantial research has advanced knowledge of the clinical features and epidemiology of TD, many fundamental questions raised by early investigators remain unresolved. In this paper, we review the early clinical reports that led to the acceptance of TD as an iatrogenic disorder and the lingering controversies that emerged thereafter. Continued research on TD as a serious adverse reaction to treatment may not only enhance patient outcomes and recovery efforts but may also provide insights into both the mechanism of action of antipsychotic drugs and the nosology and pathophysiology of idiopathic psychomotor disorders.
迟发性运动障碍(TD)是一种与多巴胺受体阻断剂相关的持续性运动障碍,包括抗精神病药物。尽管自 60 年前首次发现这种药物副作用以来,人们对其不确定性和担忧一直在波动,但最近对开发有效治疗方法的商业兴趣在长期忽视之后重新激起了科学界和临床界的兴趣。尽管大量研究已经提高了对 TD 的临床特征和流行病学的认识,但早期研究人员提出的许多基本问题仍未得到解决。在本文中,我们回顾了导致 TD 被接受为医源性疾病的早期临床报告,以及此后出现的挥之不去的争议。继续研究 TD 作为治疗的严重不良反应,不仅可能提高患者的治疗效果和康复努力,还可能为抗精神病药物的作用机制以及特发性运动障碍的分类学和病理生理学提供新的见解。